文献速递血液净化与透析

美国透析合并房颤患者的房颤治疗与结局的种族/民族差异

Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States.
PubMed 文献 · J Am Soc Nephrol · 2020-02-20

研究基于美国肾脏数据系统,纳入2006至2013年起始血液透析并后续诊断房颤的ESKD患者56587例,随访1年。黑人和西班牙裔及亚裔患者卒中发生率高于白人,但华法林处方填写率更低;华法林使用与卒中率降低相关,若华法林使用均等化可减少部分超额卒中。

要点

  • 透析合并房颤患者中,黑人和西班牙裔及亚裔的卒中发生率高于白人。
  • 上述少数族裔华法林处方填写率低于白人,华法林使用与卒中率降低相关。
  • 华法林使用均等化可预防部分超额卒中,但差异原因尚不明确。

核心结论

  • 透析合并房颤患者中,黑人和西班牙裔及亚裔的全因卒中差异部分由抗凝药使用较低所介导。

研究设计与样本

  • 基于美国肾脏数据系统识别2006至2013年起始血液透析并后续诊断房颤且具有Medicare Part A/B/D的ESKD患者,随访1年。

主要发现

  • 研究纳入56587例ESKD血液透析合并房颤患者,黑人占19%,白人占69%,西班牙裔占8%,亚裔占3%。
  • 与白人相比,黑人、西班牙裔和亚裔患者更可能发生卒中(分别为13%、15%、16%),但更少填写华法林处方(分别为10%、17%、28%)。
  • 华法林处方与卒中率降低相关;华法林分布均等化至白人水平可预防黑人、西班牙裔和亚裔患者中7%、10%、12%的超额卒中。
  • 未发现全因死亡率或心血管疾病操作使用方面的种族/民族差异。

临床怎么用

  • 应关注透析合并房颤少数族裔患者的抗凝治疗不足,并进一步研究优化卒中预防的策略。

局限性

  • 差异原因尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because stroke prevention is a major goal in the management of ESKD hemodialysis patients with atrial fibrillation, investigating racial/ethnic disparities in stroke among such patients is important to those who could benefit from strategies to maximize preventive measures. METHODS: We used the United States Renal Data System to identify ESKD patients who initiated hemodialysis from 2006 to 2013 and then identified those with a subsequent atrial fibrillation diagnosis and Medicare Part A/B/D. Patients were followed for 1 year for all-cause stroke, mortality, prescription medications, and cardiovascular disease procedures. The survival mediational g-formula quantified the percentage of excess strokes attributable to lower use of atrial fibrillation treatments by race/ethnicity. RESULTS: The study included 56,587 ESKD hemodialysis patients with atrial fibrillation. Black, white, Hispanic, and Asian patients accounted for 19%, 69%, 8%, and 3% of the population, respectively. Compared with white patients, black, Hispanic, or Asian patients were more likely to experience stroke (13%, 15%, and 16%, respectively) but less likely to fill a warfarin prescription (10%, 17%, and 28%, respectively). Warfarin prescription was associated with decreased stroke rates. Analyses suggested that equalizing the warfarin distribution to that in the white population would prevent 7%, 10%, and 12% of excess strokes among black, Hispanic, and Asian patients, respectively. We found no racial/ethnic disparities in all-cause mortality or use of cardiovascular disease procedures. CONCLUSIONS: Racial/ethnic disparities in all-cause stroke among hemodialysis patients with atrial fibrillation are partially mediated by lower use of anticoagulants among black, Hispanic, and Asian patients. The reasons for these disparities are unknown, but strategies to maximize stroke prevention in minority hemodialysis populations should be further investigated.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Waddy SP, Solomon AJ, Becerra AZ, et al. Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States. J Am Soc Nephrol. 2020. PMID: 32079604. doi:10.1681/ASN.2019050543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。